4月15日 - ** 放射中心运营商RadNet RDNT.O股价在延时交易中下跌2%，至52美元
** RDNT称 (link)，该公司正在收购人工智能乳腺癌检测软件制造商iCAD ICAD.O，此次全股票收购的价值约为1.03亿美元。
** RDNT将以每股3.61美元的价格收购ICAD普通股，与ICAD周二的收盘价相比溢价87%。
** iCAD 股票在延时交易中上涨 73%，报收于 3.31 美元
** 预计交易将于 2025 年第二或第三季度完成
** RDNT称，该交易预计将为其网络增加遍布50个国家的1500多个医疗机构网点
** 截至上一交易日收盘，RDNT下跌24%，ICAD上涨5.5%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.